Indian companies are taking center stage in Complex Generics at US and EU markets. In Bio-similars, Indian companies will have perhaps the largest basket aimed at Emerging Countries in 2014-16 and later for Developed countries. Though few but is the beginning of NCE/mAb ..."
GBI Research, the leading business intelligence provider has released its latest research report, "Biopharmaceutical Manufacturing in India, China and South Korea Regulatory Framework, Infrastructure Support and Discovery Funding Create an Environment Conducive to Growth". The re ..."